Itonis Inc (ITNS)

$0.00 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 172,100
Avg Vol 635,042
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is h...

Industry: Medical Distribution
Sector: Healthcare
Phone: 949-200-8887
Address:
22951 Mill Creek Drive, Suite A-1, Laguna Hills, United States
trprofit
trprofit Jan. 15 at 8:06 PM
$ITNS Truly a shame that this did NOTHING after the announcement of the licensing deal!
0 · Reply
trprofit
trprofit Jan. 11 at 9:38 PM
$ITNS Contract Details https://contracts.justia.com/companies/caring-brands-inc-103547/contract/1352853/
0 · Reply
trprofit
trprofit Jan. 8 at 4:31 PM
$ITNS AI View of Licensing deal with Caring Brands Sales of the over-the-counter (OTC) nausea relief product Emesyl are managed by Caring Brands Inc.. Caring Brands recently secured an exclusive global license to manufacture, market, and distribute the product, which was previously owned by Itonis Inc.. Current Status of Emesyl Sales License Agreement: As of early January 2026, Caring Brands has the sole worldwide rights to the product. Commercialization Plan: Caring Brands is assuming responsibility for the entire sales strategy, including manufacturing, marketing, and global distribution. Market Opportunity: The company sees a significant market opportunity, citing a projected global nausea treatment market value exceeding $6.23 billion in 2025. Sales Launch: The news articles indicate that the company plans to "revitalize and scale Emesyl's market presence" and are expected to launch a total of five products over the next two years.
0 · Reply
trprofit
trprofit Jan. 7 at 2:14 PM
$ITNS An investor has to love this headline! https://www.theglobeandmail.com/investing/markets/markets-news $6.23 Billion Market Opportunity Via Exclusive Global License to Manufacture and Sell Emesyl OTC Nausea Relief Product by Caring Brands Inc. (Nasdaq: CABR)
0 · Reply
trprofit
trprofit Jan. 6 at 1:08 PM
$ITNS LICENSING DEAL JUST ANNOUNCED! Well, they just may have something happening.....FINALLY! https://www.tradingview.com/news/tradingview:ede01069177b1:0-caring-brands-signs-license-agreement-with-itonis-
0 · Reply
trprofit
trprofit Nov. 26 at 12:44 PM
$ITNS Note all the 2662 buys. WTF?
0 · Reply
trprofit
trprofit Jul. 24 at 2:53 PM
$ITNS Quarterly out. NO mention of CVS!
0 · Reply
trprofit
trprofit Mar. 13 at 7:09 PM
$ITNS AR is out and contains the same In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock.
0 · Reply
trprofit
trprofit Mar. 11 at 11:37 AM
$ITNS Still breathing, eh? Note the 3333 share trades
0 · Reply
skagnetti13
skagnetti13 Jan. 24 at 12:28 AM
$ITNS How many others are trapped in here with me??🤣
0 · Reply
Latest News on ITNS
No data available.
trprofit
trprofit Jan. 15 at 8:06 PM
$ITNS Truly a shame that this did NOTHING after the announcement of the licensing deal!
0 · Reply
trprofit
trprofit Jan. 11 at 9:38 PM
$ITNS Contract Details https://contracts.justia.com/companies/caring-brands-inc-103547/contract/1352853/
0 · Reply
trprofit
trprofit Jan. 8 at 4:31 PM
$ITNS AI View of Licensing deal with Caring Brands Sales of the over-the-counter (OTC) nausea relief product Emesyl are managed by Caring Brands Inc.. Caring Brands recently secured an exclusive global license to manufacture, market, and distribute the product, which was previously owned by Itonis Inc.. Current Status of Emesyl Sales License Agreement: As of early January 2026, Caring Brands has the sole worldwide rights to the product. Commercialization Plan: Caring Brands is assuming responsibility for the entire sales strategy, including manufacturing, marketing, and global distribution. Market Opportunity: The company sees a significant market opportunity, citing a projected global nausea treatment market value exceeding $6.23 billion in 2025. Sales Launch: The news articles indicate that the company plans to "revitalize and scale Emesyl's market presence" and are expected to launch a total of five products over the next two years.
0 · Reply
trprofit
trprofit Jan. 7 at 2:14 PM
$ITNS An investor has to love this headline! https://www.theglobeandmail.com/investing/markets/markets-news $6.23 Billion Market Opportunity Via Exclusive Global License to Manufacture and Sell Emesyl OTC Nausea Relief Product by Caring Brands Inc. (Nasdaq: CABR)
0 · Reply
trprofit
trprofit Jan. 6 at 1:08 PM
$ITNS LICENSING DEAL JUST ANNOUNCED! Well, they just may have something happening.....FINALLY! https://www.tradingview.com/news/tradingview:ede01069177b1:0-caring-brands-signs-license-agreement-with-itonis-
0 · Reply
trprofit
trprofit Nov. 26 at 12:44 PM
$ITNS Note all the 2662 buys. WTF?
0 · Reply
trprofit
trprofit Jul. 24 at 2:53 PM
$ITNS Quarterly out. NO mention of CVS!
0 · Reply
trprofit
trprofit Mar. 13 at 7:09 PM
$ITNS AR is out and contains the same In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock.
0 · Reply
trprofit
trprofit Mar. 11 at 11:37 AM
$ITNS Still breathing, eh? Note the 3333 share trades
0 · Reply
skagnetti13
skagnetti13 Jan. 24 at 12:28 AM
$ITNS How many others are trapped in here with me??🤣
0 · Reply
NevD
NevD Jan. 8 at 4:16 AM
$ITNS
0 · Reply
NevD
NevD Jan. 2 at 4:00 PM
$ITNS this need 0.0006 or better.
0 · Reply
trprofit
trprofit Nov. 25 at 7:20 PM
$ITNS QUARTERLY 10/27/24 INFO THE SAME In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock
1 · Reply
NevD
NevD Oct. 8 at 7:54 PM
$ITNS I bought this in the Pennie’s… 🥺
1 · Reply
NevD
NevD Aug. 22 at 9:34 PM
$ITNS
0 · Reply
trprofit
trprofit Jul. 31 at 11:49 PM
$ITNS Quarterly was out July 20. Same info as last one (CVS and Smart Cannabis Inc.) Maybe something will actually happen!!!!!!
2 · Reply
trprofit
trprofit May. 31 at 1:51 PM
$ITNS Back to pink current. Why bother, unless......?
0 · Reply
skagnetti13
skagnetti13 May. 30 at 2:21 AM
$ITNS What the hell is going on here?? Same pattern almost every single day. Some days close at .004 and some at .005. No news, no fillings, weird company.
0 · Reply
trprofit
trprofit May. 2 at 12:03 PM
$ITNS So....is something happening or not?
2 · Reply
trprofit
trprofit Apr. 16 at 11:12 AM
$ITNS Quarterly also referenced this: On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock." Smart Cannabis Corp. (SCNA) .0002
0 · Reply
trprofit
trprofit Apr. 16 at 11:11 AM
$ITNS Quarterly out yesterday. Referenced this: "In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market."
0 · Reply
skagnetti13
skagnetti13 Apr. 8 at 3:28 PM
$ITNS Morning all!! Just hopped in with 2 mil shares.
0 · Reply